Abstract
Aim: The objective of this study was to explore the cost-effectiveness of D-dimer biomarker and the societal value (headroom) of a hypothetical perfect biomarker for risk assessment and subsequent treatment stratification of prophylactic treatment for peripheral arterial disease (PAD). Patients & methods: Decision analytic modeling. Results: Use of the D-dimer biomarker to prescribe oral anticoagulants in the high-risk subset of patients is a cost-effective healthcare intervention. The headroom (societal willingness to pay multiplied by incremental quality-adjusted life years) available for the hypothetical perfect biomarker amounted to (sic)83,877. Conclusion: D-dimer-based PAD risk assessment and treatment tailoring is cost effective. Identification of high-risk PAD patients and prescription of oral anticoagulants could potentially save substantial costs and improve chances of survival for high-risk PAD patients. However, further research of risk stratifying biomarkers test accuracy is needed to support and strengthen the results of this modeling study.
| Original language | English |
|---|---|
| Pages (from-to) | 989-999 |
| Number of pages | 11 |
| Journal | Biomarkers in Medicine |
| Volume | 8 |
| Issue number | 8 |
| DOIs | |
| Publication status | Published - 1 Jan 2014 |
Keywords
- cost-effectiveness analysis
- D-dimer
- decision modeling
- peripheral arterial disease
- risk assessment
- ORAL ANTICOAGULANTS
- EVENT RATES